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Osteosarcoma (OS) is themost commonprimarymalignancy of bone.Mortality is determined by the presence ofmetastatic disease,
but little is known regarding the biochemical events that drive metastases. Twomurine OS cell lines, K7M2 and K12, are related but
differ significantly in their metastatic potentials: K7M2 is highly metastatic whereas K12 displays much less metastatic potential.
Using this experimental system, the mammalian target of rapamycin (mTOR) pathway has been implicated in OS metastasis. We
also discovered that aldehyde dehydrogenase (ALDH, a stem cell marker) activity is higher in K7M2 cells than K12 cells. Rapamycin
treatment reduces the expression and enzymatic activity of ALDH in K7M2 cells. ALDH inhibition renders these cells more
susceptible to apoptotic death when exposed to oxidative stress. Furthermore, rapamycin treatment reduces bone morphogenetic
protein-2 (BMP2) and vascular endothelial growth factor (VEGF) gene expression and inhibits K7M2 proliferation, migration, and
invasion in vitro. Inhibition of ALDH with disulfiram correlated with decreased mTOR expression and activity. In conclusion, we
provide evidence for interaction between mTOR activity, ALDH activity, and metastatic potential in murine OS cells. Our work
suggests that mTOR and ALDH are therapeutic targets for the treatment and prevention of OS metastasis.
1. Introduction
Osteosarcoma (OS), the most common primary malignancy
of bone, usually occurs in the long bones during childhood
and adolescence at sites of rapid bone turnover [1–3]. Despite
pre- and postoperative chemotherapy and wide surgical
resection of the tumor, overall survival for patients without
radiographically detectable metastases is only 65–70% [1, 2,
4, 5, 8]. The prognosis for patients with detectable metastases
at the time of diagnosis is particularly poor, ranging from 15
to 30% [1, 7, 8]. It is thus the presence of pulmonarymetastatic
disease that ultimately determinesOSmortality [9].However,
little is known about the biochemical signaling pathways
that drive the progression of metastases and the molecular
biology ofOS remains poorly understood.As a result, we have
yet to develop therapeutic strategies that specifically target
metastatic disease.
The mammalian target of rapamycin (mTOR) is a highly
conserved serine/threonine kinase, and as its name implies,
mTOR activity is specifically inhibited by the drug rapamycin
[10–13]. Rapamycin is an antimicrobial agent produced by
Streptomyces hygroscopius that also exhibits potent immuno-
suppressive and antitumor properties, likely due to its ability
to arrest the cell cycle in G1-phase [14]. mTOR signaling
regulates a number of critical cellular processes including
cellular growth, metabolism, and aging via an extraordinarily
complex intercellular signaling network [15, 16]. Dysreg-
ulation of this mTOR signaling network can participate
in a variety of human disease processes including cancer
[17].
In mammals, mTOR associates with the proteins Raptor
or Rictor to form mTOR complexes 1 and 2 (mTORC1 and
2), respectively. mTORC1 activity is sensitive to rapamycin,
whereas mTORC2 is not [18, 19]. The best characterized
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substrates of mTORC1 are p70 ribosomal protein S6 kinase
(S6K1) and the eukaryotic initiation factor 4E-binding pro-
tein 1 (4E-BP1), through which mTOR activity can regulate
protein synthesis and cell growth [17]. A role for rapamycin-
sensitive and rapamycin-insensitive mTOR signaling in cell
motility and cancer metastasis is evolving but our current
understanding is limited [14]. It is, however, widely recog-
nized that mTOR signaling plays a critical role in protein
synthesis, cell proliferation, growth, and survival [10, 20–
22]. Dysregulated mTOR signaling is found in a variety of
human cancers including hematologic, lung, breast, liver,
pancreas, renal, skin, and gastrointestinal tract neoplasms
[17]. In addition, it was recently discovered that mTOR
signaling is activated in human osteosarcoma and correlates
with surgical stage, metastasis, and disease-free survival [23].
The primary goal of this study was to investigate the role of
mTOR signaling in OS metastasis and mTOR inhibition with
rapamycin.
K7M2 and K12 are related murine OS cell populations
derived from the same spontaneously-occurring OS in a
Balb-C mouse. K7M2 cells are highly metastatic to the lungs
and were clonally derived from the much less metastatic
K12 cells [24]. K7M2 and K12 cells are thus very similar
genetically but differ significantly in their metastatic poten-
tials. As such, they represent excellent tools for determin-
ing critical biochemical pathways in OS metastasis. It has
been reported that mTOR signaling activity is enhanced in
K7M2 cells compared to K12 cells [25]. Here we report that
mTOR signaling in K7M2 cells is associated with higher
aldehyde dehydrogenase (ALDH, a cancer stem cell marker)
activity, increased resistance to oxidative stress, increased
proliferation, migration, and invasion, and higher bone
morphogenetic protein (BMP2) and vascular endothelial
growth factor (VEGF) expression than in the less metastatic
K12 cells. All of these metastatic phenotypes were reversed
with rapamycin treatment. Interestingly, we also report that
ALDH inhibitionwith disulfiram is correlatedwith decreased
mTORactivity and causesmorphological alterations toK7M2
cells. This study provides evidence that the mTOR pathway
promotes ALDH activity and metastatic potential in OS
cells. We conclude that mTOR and ALDH are potential
therapeutic targets in the treatment and prevention of OS
metastasis.
2. Materials and Methods
2.1. Cell Culture and Rapamycin Treatment. K7M2 cells and
K12 cells were cultured with proliferation medium (PM;
DMEM with 10% FBS and 5% penicillin and streptomycin).
For mTORC1 inhibition of K7M2 cells, rapamycin (Sigma)
was dissolved in DMSO (10mM) and diluted 1 : 1000 in
proliferation medium to a working concentration of 10 𝜇M.
K7M2 cells were seeded in 12-well plastic plates at 5,000 cells
per well, and 1mL treatment medium containing rapamycin
was added to each well. 1mL of medium containing the same
amount of DMSO served as control treatment. Treatment
medium was refreshed each day and cells were treated for 2
to 4 days.
2.2. Fluorescence-Activated Cell Sorting (FACS) Analysis of
ALDH Activity and Sorting of Cells. The Aldelfluor Kit
(STEMCELL Technologies) was used to determine ALDH
enzymatic activity. Cultured K7M2 cells andK12 cells, with or
without rapamycin treatment (10 𝜇M for 48 hrs), were resus-
pended inAldefluor buffer (1× 106 cells/mL) and incubated at
37∘C according to the manufacturer’s instructions. Cells were
washed in Aldefluor buffer and maintained in 4∘C through-
out the cell sorting process. ALDHactivity was assessed using
the FL1 channel of a BD FACSAria Cell Sorting System and
FACSDiva software (version 6.1.2; Becton, Dickinson and
Company, San Jose, CA). Collected cells were sorted with
fluorescence-activated cell sorting (FACS), according to their
fluorescence intensity, which corresponds to their ALDH
activity levels, as well as low side scatter (SCClo). ALDH-
high cells and ALDH-low cells were separately harvested and
cultured.
2.3. Cell Proliferation Assay. K7M2 and K12 cells were plated
at 1000 cells per well in a 12-well plate and cultured in PM.
A time-lapsed microscopic live-cell imaging (LCI) system
(Automated Cell, Inc.) was used to take images of cells per
each field of view at 15 minute intervals for 4 days. The
approximate population doubling time (PDT) as determined
as follows: 2𝑛 = cell number at harvest time/cell number
initially plated; “𝑛” refers to the number of doublings during
the period of cell culture (96 hrs), thus PDT = 96 hrs/𝑛.
2.4. Cell Survival Assay after Exposure to Oxidative Stress.
The antioxidant capacities of K7M2 (unsorted, ALDH-high,
and ALDH-low fraction) and K12 cells cultured in 12-well
plastic plates were compared by exposure to oxidative stress
(250 𝜇MH
2
O
2
in PM) for 6 hrs. Also, to test the role ofmTOR
inhibition on the antioxidant capacity of K7M2 cells, K7M2
cells were pretreated with rapamycin (10𝜇M) for 48 hrs prior
to exposure to oxidative stress (0, 250, or 500𝜇M H
2
O
2
in
PM) conditions for 6 hours. Propidium iodide (PI) was added
to the medium (1 𝜇g/mL) and apoptotic cells were identified
with positive PI staining.
2.5. In Vitro Single Cell Migration Assay. An automated time-
lapsed microscopy system (Biorad) was used to track the
single cell migration on plastic surface. Cells were observed
at 15 minute increments over 96 hours, the composite images
were analyzed, the tracks of migration of 10 preselected single
cells were monitored for each cell group, and cell velocities
were calculated.
2.6. Cell In Vitro Invasion Assay. In vitro invasion capacity
of K7M2 cells with or without rapamycin treatment, as
well as ALDH-high and ALDH-low fractions of untreated
K7M2 cells, was assessed using a real-time cell invasion
and migration (RT-CIM) assay system (ACEA Biosciences,
Inc.), with a 16-well trans-well plate (CIM-plate 16, Roche
Diagnostics GmbH). The surface of the wells in the upper
chamber was coated withMatrigel (BD BioSciences, Bedford,
MA USA) of different concentrations (2.5%, 5%, and 10%).
Serum-containing medium (10% FBS) was added to the wells
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Table 1: Primer Sequences.
Gene Primer sequence Band size (bp)
GAPDH Forward: TCCATGACAACTTTGGCATTG 103
Reverse: TCACGCCACAGCTTTCCA
BMP2 Forward: TCTTCCGGGAACAGATACAGG 126
Reverse: TGGTGTCCAATAGTCTGGTCA
BMP4 Forward: ATTCCTGGTAACCGAATGCTG 89
Reverse: CCGGTCTCAGGTATCAAACTAGC
VEGF Forward: GCCAGACAGGGTTGCCATAC 108
Reverse: GGAGTGGGATGGATGATGTCAG
c-Myc Forward: TGACCTAACTCGAGGAGGAGCTGGAATC 170
Reverse: AAGTTTGAGGCAGTTAAAATTATGGCTGAAGC
ALDH Forward: GACAGGCTTTCCAGATTGGCTC 142
Reverse: AAGACTTTCCCACCATTGAGTGC
mTOR Forward: CAGTTCGCCAGTGGACTGAAG 130
Reverse: GCTGGTCATAGAAGCGAGTAGAC
of the lower chamber. Cells (4 × 104 per well) in serum-free
mediumwere seeded in the upper chamber.Themigration of
the cells through the Matrigel was monitored by the system
every 15 minutes for 24 hours. Data analysis was carried out
using RTCA Software 1.2 supplied with the instrument.
2.7. Semiquantitative Reverse Transcription Polymerase Chain
Reaction (RT-PCR). Total RNA was extracted from the cells
using the RNeasy plus mini kit (Qiagen) and cDNA was gen-
erated using the iScript cDNA Synthesis kit (Bio-Rad). The
sense and antisense primers for RT-PCR and their product
sizes are found in Table 1. The cycling parameters used for
all reactions were as follows: 94∘C for 5 minutes; 30 cycles
of the following: denature for 45 seconds at 95∘C, anneal
for 30 seconds (53∘C–56∘C), and extend for 45 seconds at
72∘C. RT-PCRwas performed using a Bio-RadMyiQ thermal
cycler (Bio-Rad). GAPDH served as a control gene, and the
expression of target genes was normalized to the expression
of GAPDH. Gradient dilution (1 : 1, 1 : 2, and 1 : 4) of RNA
samples from different cell groups was compared respectively
to verify the quantitative difference of gene expression. RT-
PCR analysis was performed using ImageJ software (version
1.32j, National Institutes of Health, Bethesda, MD) where the
integrated density (product of the area and the mean gray
value) of bands was calculated. All molecular bands were
normalized to GAPDH.
2.8. Actin Staining. Organization of actin in ALDH-high,
ALDH-low, and disulfiram treated cells was assessed using
the phalloidin conjugated with Alexa Fluor 488 (Invitrogen).
Populations of ALDH-high and ALDH-low cells were plated
on to 12 well plates (50,000 cells/plate) and grown overnight
in proliferation medium. The following day, the plates were
washed twice with PBS, fixed in 3.7% formaldehyde solution
for 10 minutes at room temperature, and washed two more
times with PBS. The cells were then permeabilized in 0.1%
Trition X-100 for 20 minutes and washed again with PBS.
For each well a staining solution of 5𝜇L of methanolic stock
solution phalloidin with 200𝜇L PBS and 1% BSA was added.
The staining solution was kept in the wells for 20 minutes,
and then the wells were washed again with PBS. This made
the actin appear green under a fluorescence microscope.
The nucleus was stained by adding 300 𝜇L of 300 nM DAPI
to wells for 5 minutes and then rising twice with PBS.
This made the nucleus appear blue under a fluorescence
microscope.
2.9. Disulfiram Treatment. Disulfiram is an ALDH inhibitor
that has been used to treat alcoholism by blocking the
enzymatic conversion of ethanol to acetic acid. In this study
it was used to determine the effect of blocking ALDH in
K7M2 cells vis-a`-vis mTOR activity and cell morphology.
ALDH-high andALDH-low cells were plated and left to grow
for approximately 2 hours before adding the disulfiram. A
concentration of 250 nM was found to be the high nontoxic
concentration able to be used on the cells.
2.10. mTOR Immunostaining. In order to determine the
relative expression of mTOR in disulfiram-treated versus
untreated cells, the cells were incubated with p-4E-BP1 (a
rabbit antibody to mTOR). After a period of 2 hours, the cells
were rinsed and then incubated with a fluorescent anti-rabbit
antibody for one hour.The cells were then treated with DAPI
as described earlier in order to visualize the nuclei. Pictures
were then taken with a fluorescence microscope.
2.11. Statistical Analysis. At least three samples obtained from
each subject were pooled for statistical analysis of all results
from this study, and the results are expressed as a mean ±
SD. The differences between two means were considered to
be statistically significant if 𝑃 value was <0.05. A Student’s t-
test was used to determine statistically significant differences
between two means.
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Figure 1: Phospho-4E-BP1 levels and rapamycin-sensitive gene expression in murine OS cells. (a) Immunofluorescence analysis of K7M2
and K12 cells depicting phospho-4E-BP1 (p-4E-BP1) counterstained with DAPI. (b) Quantitative analysis of p-4E-BP1 staining comparing
the percentage of positive K7M2 and K12 cells. (c) RT-PCR was performed on cellular RNA extracted from K7M2 and K12 cells in order to
quantitate the relative expression of BMP2, BMP4, VEGF, and ALDH-1A1. GAPDH serves as a loading control. (d) RT-PCR was performed
on cellular RNA extracted from K7M2 cells treated with rapamycin or DMSO only (K7M2) in order to quantitate the relative expression
of BMP2, VEGF, and ALDH-1A1 in the presence of mTORC1 kinase inhibition. Again, GAPDH serves as a loading control. Asterisks (∗)
indicate statistically significant differences (𝑃 < 0.05).
3. Results
3.1. Rapamycin Inhibits BMP2, VEGF, and ALDH-1A1 Gene
Expression in K7M2 Cells. K7M2 cells are known to exhibit
greater mTORC1 kinase activity [25]. In order to confirm
elevated mTORC1 kinase activity in our K7M2 cells we com-
pared the amount of its phosphorylated substrate, phospho-
4E-BP1 (p-4E-BP1), in K7M2 and K12 cells by immunoflu-
orescence using a phosphospecific antibody (anti-phospho-
threonine-37/46). Figure 1(a) shows a representative image
of fixed K7M2 and K12 cell populations processed for p-
4E-BP1 and DAPI immunofluorescence. Consistent with
published results [25], we observed a greater than twofold
increase in p-4E-BP1 immunofluorescence in K7M2 cultures
compared to K12 cultures (Figure 1(b)), suggestive of ele-
vated mTORC1 kinase activity in the more metastatic K7M2
cells.
ALDH activity, a “cancer stem cell marker,” is found
in a variety of human cancers and has been associated
with metastasis, drug resistance, and a poor prognosis [26–
30]. In order to investigate the role of mTORC1 activity in
the regulation of ALDH in K7M2 cells we first performed
reverse transcription polymerase chain reaction (RT-PCR)
using RNA extracted from K7M2 and K12 cells treated with
rapamycin or DMSO control. We have previously shown
that BMP2 and VEGF expressions are upregulated in K7M2
cells compared to K12 cells [31]. Therefore, we analyzed
the expression of BMP2, BMP4, and VEGF, in addition to
ALDH-1A1 expression. GAPDH served as a loading control.
Figure 1(c) shows the upregulation of these genes, except
BMP4, in K7M2 cells compared to K12 cells, in the absence of
rapamycin. After the addition of rapamycin to the media, we
observed a significant down-regulation of BMP2, VEGF, and
ALDH-1A1 mRNA transcripts of K7M2 cells (Figure 1(d)).
3.2. Rapamycin Treatment Reduces ALDH Activity and Sen-
sitizes K7M2 Cells to Oxidative Stress. In order to further
investigate the effect of rapamycin on ALDH we performed
fluorescence-associated cell sorting (FACS) analysis to quan-
titate the percentage of cells with ALDH activity. Consistent
with our RT-PCR results, we observed a threefold increase
in the percentage of K7M2 cells with ALDH activity (23.1 ±
3.5% versus 7.4 ± 2.7%) compared to K12 cells (Figure 2(a)).
However, after rapamycin treatment, the percentage of K7M2
cells with ALDH activity reduced significantly, compared to
DMSO control group, and approached a level of activitymore
comparable to the less metastatic K12 cells (Figure 2(b)).
After observing that rapamycin effectively reduced
ALDH-1A1 expression and ALDH activity in K7M2 cells,
we next wanted to investigate the effect of rapamycin treat-
ment on K7M2 resistance to oxidative stress because the
activity of ALDH in cancer may function to neutralize
oxidative stress and provide chemoresistance [32, 33]. We
tested resistance to oxidative stress using H
2
O
2
treatment.
Apoptosis was monitored by nuclear inclusion of propidium
iodide (PI). Figure 2(c) contains representative images of
K7M2 cells and K12 cells treated with or without H
2
O
2
.
After treatment with H
2
O
2
, the large majority (>85%) of
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Figure 2: Rapamycin treatment reduces ALDH activity and sensitizes K7M2 cells to oxidative stress. (a) ALDH activity was detected in K7M2
and K12 cells using FACS analysis and the relative amount of cells positive for ALDH is shown for each cell population. (b) K7M2 cells were
treated with rapamycin or DMSO only (control) and analyzed by FACS as in (a). (c) K7M2 and K12 cells were treated with or without H
2
O
2
(250𝜇M) and apoptosis was detected using PI staining. (d) A quantitative analysis of (c) illustrating the percentage of apoptotic cells after
H
2
O
2
treatment compared to untreated controls. (e) K7M2 cells were treated with or without H
2
O
2
, in the presence or absence (DMSO only
control) of rapamycin, and apoptotic cells were detected as in (c). (f) A quantitative analysis of (e) illustrating the percentage of apoptotic
cells after H
2
O
2
compared to untreated controls. Asterisks (∗) indicate statistically significant differences (𝑃 < 0.05).
K12 cells underwent apoptosis as indicated by PI inclu-
sion, whereas most of the K7M2 cells maintained viability
(>65%) as indicated by nuclear exclusion of PI (Figure 2(d)).
Therefore, K7M2 cells are more resistant to oxidative stress
from H
2
O
2
exposure than K12 cells. In order to test if
this resistance to H
2
O
2
was related to mTORC1 or ALDH
activity we repeated these experiments on K7M2 cells in the
presence or absence of rapamycin, and 0 𝜇M or 250𝜇M of
H
2
O
2
. Representative images are shown in Figure 2(e). We
observed an increased sensitivity to H
2
O
2
with rapamycin
treatment as rapamycin caused a threefold increase in apop-
tosis (Figure 2(f)). Rapamycin alone is not proapoptotic in
this assay, as rapamycin in the absence of H
2
O
2
did not
increase the frequency of PI nuclear inclusion in K7M2
cells.
3.3. Rapamycin Treatment Reduces K7M2 Cell Proliferation.
We analyzed K7M2 cell proliferation with and without
rapamycin treatment because rapamycin has been shown
to induce a G1-arrest in many tumor cell lines including
osteosarcoma [10, 34]. After four days of culture in the
presence or absence of rapamycin, K7M2 cells cultured in
the presence of rapamycin appeared less dense on the culture
dishes (Figure 3(a)). We then determined the population
doubling time (PDT) of K7M2 and K12 cells with or with-
out rapamycin treatment, over a culture period of 4 days
(Figures 3(b) and 3(c)). It showed that PDT of both K7M2
and K12 was increased by rapamycin treatment, while its
effect on K7M2 cells is more profound than that of K12
cells.
3.4. Rapamycin Treatment Reduces K7M2 Cell Migration
and Invasion. K7M2 cells display much greater metastatic
potential in vivo compared to K12 cells [24]. Consistent with
this enhanced metastatic ability, we performed an in vitro
tracking cell migration assay and observed more migratory
activity in K7M2 cells compared to K12 cells and both K7M2
and K12 migration was sensitive to rapamycin (Figure 4(a)).
We then determined the velocity of cell migration in this
assay and the results are similar and displayed in Figure 4(b).
Lastly, we evaluated the invasion capacity of K7M2 and K12
cells in 2.5% Matrigel and found that K7M2 cells have much
stronger invasion capacity than K12 cells (data not shown).
Furthermore, it was found that rapamycin greatly reduces
K7M2 cell invasion in this assay (Figure 4(c)).
3.5. ALDH-High K7M2 Cells Have Greater Invasiveness,
Morphologic Changes, Resistance to Oxidative Stress, and
Expression of Oncogenic Factors Than ALDH-Low K7M2
Cells. K7M2 cells have been sorted according to the dif-
ferential ALDH activity. The sorted populations of ALDH-
high and ALDH-low K7M2 cells have been expanded in
vitro (Figure 5(a)). In vitro invasion assay with 2.5% Matrigel
demonstrated that ALDH-high K7M2 cells have much
higher invasion capacity compared to ALDH-low K7M2
cells (Figure 5(b)). ALDH-high K7M2 cells were found to
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Figure 3: Rapamycin treatment reduces K7M2 cell proliferation. (a) K7M2 cells were cultured with media containing 10𝜇M rapamycin or
DMSO only (control) for four days. Representative images of cell density at the beginning and end of treatment are shown. (b) A quantitative
analysis of (a) to determine the population doubling time (PDT) of K7M2 cells in rapamycin-treated and control groups (DMSO only). (c) A
quantitative analysis determining the population doubling time (PDT) of K12 cells in rapamycin-treated and control groups (DMSO only).
Asterisks (∗) indicate statistically significant differences (𝑃 < 0.05).
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Figure 4: OS cell migration and invasion is sensitive to rapamycin treatment. (a) K7M2 and K12 cell migration was tracked in the presence
or absence (DMSO only control) of rapamycin (10 𝜇M) and the data obtained is displayed. (b) The velocity of cell migration was determined
in each group in (a) and the results are displayed. (c) K7M2 cell invasion through a 2.5%Matrigel was monitored for 18 hours in the presence
or absence (DMSO only) of 10𝜇M rapamycin. Asterisks (∗) indicate statistically significant differences (𝑃 < 0.05).
be more spread out and irregular in shape than ALDH-
low K7M2 cells. They also displayed characteristics of typ-
ical motile behavior such as more organized structure of
actin and the presence of filopodia (Figure 5(c)). Certain
types of filopodia have been associated with increased
invasiveness and metastasis rate [35]. Antioxidative stress
assay showed that ALDH-high K7M2 cells are more resis-
tant to the treatment of hydrogen peroxide, compared to
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Figure 5: Cell sorting of K7M2 cells via ALDH activity and differential features of ALDH-high cells and ALDH-low cells. (a) K7M2 cells
were suspended in Aldefluor buffer and sorted according to their fluorescence. Cells were treated with DEAB to block ALDH fluorescence,
and cells were deemed ALDH-high if their fluorescence was higher than that of the DEAB-treated controls. Cells were deemed ALDH-low if
their fluorescence was lower than that of the DEAB-treated controls. (b) ALDH-high and ALDH-low K7M2 cell invasion was tracked over a
period of 24 hours and the data obtained is displayed. The ALDH-high cells displayed a much higher invasion potential, with more fraction
of cells invading through the matrigel (2.5%). (c) Under bright field microscopy and under fluorescent microscopy (after staining for actin
(green) and nucleic acids (blue)) ALDH-high K7M2 cells displayed more filopodia than ALDH-low cells. Also the ALDH-high cells were
more irregularly shaped and were more pleomorphic than ALDH-low K7M2 cells.
ALDH-low K7M2 cells (Figure 2). RT-PCR also showed that
ALDH-high cells had a higher expression of mTOR and
c-Myc.
3.6. ALDH-High K7M2 Cells Treated with an ALDH-Inhibitor
(Disulfiram) Show Reduced ALDH Activity, Oncogene Expres-
sion, and Morphologic Alterations. ALDH-high cells treated
with disulfiram were verified to show amuch reduced ALDH
activity (data not shown). ALDH-high cells treated with
disulfiram were found to have a lower expression of mTOR
and c-Myc than untreated ALDH-high cells as shown via RT-
PCR (Figure 6(a)). Treated cells also displayed less mTOR
activity as shown via immunostaining with phosphpo-4E-
BP1 (Figure 6(b)). Finally, the addition of disulfiram altered
the cells’ morphologies: they appeared much more like
ALDH-low cells than untreatedALDH-high cells.There were
much fewer filapodia, and the cells appeared much more
uniform in shape (Figure 6(c)).
4. Discussion
K7M2 murine OS cells are highly metastatic to the lungs
and were clonally derived from the less metastatic K12 OS
cells [24]. Thus, the K7M2 and K12 cell lines are very
similar genetically but differ significantly in their metastatic
phenotypes and represent excellent tools for determining
the critical biochemical pathways of OS metastasis. Here
we report that, in comparison with K12 cells, K7M2 cells
feature “rapamycin-sensitive” mTOR signaling which pro-
motes cellular behaviors associatedwithmetastasis, including
higherALDHactivity, increased resistance to oxidative stress,
proliferation, migration, invasion, and upregulation of BMP2
and VEGF expression. These results imply that mTORC1
activity may contribute to the enhanced metastatic potential
of K7M2 cells.
There are several limitations to this study not the least
of which is that all of our experiments were performed in
vitro. Additionally, all of our experiments, and therefore our
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Figure 6: Inhibition of ALDH with disulfiram inhibits metastatic properties of ALDH-high K7M2 cells. (a) Disulfiram (250 nM) was added
to ALDH-high K7M2 cells and the cells were cultured for at least 24 hours in 10% FBS growth medium. RT-PCR was used to determine gene
expression differences as a result of this treatment, with GADPH used as a control. Both mTOR and c-Myc expression were reduced as a
result of the treatment with disulfiram. (b) Immunostaining with phospho-4E-BP1 (a mouse anti-mTOR antibody) was done to confirm that
treatment with disulfiram reduced expression of mTOR As the concentration of disulfiram was increased (0 nm, 100 nm and 500 nm) cells
displayed progressively less mTOR expression. (c) Morphologic differences after treatment with disulfriam were also present, with disulfiram
treated cells (stained for actin) appearing less pleomorphic and with fewer filopodia.
conclusions, are based entirely on the study of two murine
cell lines. Although the observations reported above are
interesting, care must be taken not to overstate these data.
Fortunately, themetastatic phenotypes of K7M2 andK12 cells
have been well-characterized in previous studies, including
the effect of rapamycin treatment on K7M2 metastasis [24,
36]. We believe that our conclusions are sound, but future
studies evaluating ALDH and mTOR activity in other OS
cell lines and in vivo will be essential to validate these
observations.
A role for mTOR signaling in osteosarcoma metastasis
is slowly evolving. Human osteosarcoma tissue samples have
stained positive for mTOR signaling and this has been corre-
lated with surgical stage, metastasis pattern, and disease-free
survival [23]. Our current understanding of the molecular
biology remains limited. It has been shown in K7M2 cells
that Ezrin (a plasma membrane to actin cytoskeleton linker
protein) expression is upregulated compared to K12 cells, and
that dynamic regulation of Ezrin activity via phosphorylation
is required for metastasis to occur in a mouse xenograft
model. It appears that Ezrin must be turned “on” and
“off” in order to regulate cellular metabolism and protect
K7M2 OS cells against stress after early arrival in the lungs.
Furthermore, Ezrin, phosphatidylinositol-3-kinase (PI3K),
and AKT are each associated with phosphorylation of S6K1
and 4E-BP1. Interestingly, Ezrin-associated phosphorylation
of S6K1 and 4E-BP1 is sensitive to rapamycin, suggesting that
these phosphorylation events depend on themTORC1 kinase
complex [25, 37].
mTOR signaling can regulate cell motility through
mTORC1 and mTORC2-dependent kinase activity. Here we
show that rapamycin can inhibit K7M2 cellmigration in vitro,
presumably by blocking mTORC1 activity. The regulation
of cell motility by mTORC1 is most likely to be the mech-
anism that influences cell migration. Both mTORC1/S6K1
and mTORC1/4E-BP1 pathways are known to regulate cell
motility. S6K1 participates in the phosphorylation of the
focal adhesion proteins and F-actin reorganization in order
to modulate cell motility but little is known about the
manner in which 4E-BP1 regulates this process [14]. Thus,
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rapamycin treatment could block migration by interfering
with mTORC1-mediated cell motility but would potentially
leave mTORC2 unchecked and free to regulate cell motility
via control of the actin cytoskeleton through activation of the
Rho GTPases [14].
ALDH activity has been identified as a “cancer stem
cell” (CSC) marker in multiple neoplasms and has been
associated with metastasis and a poor prognosis, but such a
role has yet to be established in osteosarcoma [26–30]. The
CSC hypothesis predicts that if certain genetic alterations
occur in the right context, and within a more primitive
cell, then a cancer-initiating cell is born that retains all the
qualities of stem cells including self-renewal, proliferation,
differentiation, resistance to drugs, stress, apoptosis, and
the capacity to migrate, invade, and induce angiogenesis
[38]. Our results show that ALDH-high OS cells display a
significantly greater metastatic phenotype than ALDH-low
cells. Although the relationship between CSCs andmetastasis
has not been clearly elucidated, it has been demonstrated that
the number of metastatic cancer colonies correlates with the
frequency of CSCs in the primary tissue. Furthermore, CSC
subpopulations display a higher potential for invasiveness
than subpopulations of nonstem tumor cells [39].
In this study, we observed that K7M2 cells exhibit higher
levels of ALDH activity and this is dependent on mTORC1
activity as indicated by treatment with rapamycin. Further-
more, we showed that K7M2 cells, in comparison to K12
cells, are more resistant to oxidative stress caused by H
2
O
2
treatment. The activity of ALDH in cancer may function
to neutralize oxidative stress and provide chemoresistance,
and thus upregulation of ALDH activity by mTOR may be
one mechanism that confers resistance to oxidative stress
in K7M2 cells [32, 33]. Alternatively, disulfiram, an ALDH
inhibitor, has been shown to reduce the invasiveness of U2OS
cells and the expression of matrix metalloproteinases, raising
the possibility that ALDH activity may have a more direct
role in tumor invasion [28]. However, the mechanisms for
disulfiram’s effects on U2OS invasion remain unclear.
In terms of stem cell regulation, an integral role formTOR
signaling in the proliferation and self-renewal of embryonic
stem cells (ESCs) has been implicated. Loss of mTOR activity
in human ESCs impairs pluripotency, blocks proliferation,
and enhances mesoderm and endoderm activities [40]. The
repression of developmental genes through mTOR signaling
is thought to maintain pluripotency. Differentiation induces
an “anabolic switch” and an increase in protein synthesis
and protein content coincide with cell fate determination.
Specifically, mTOR, and 4E-BP1 may function to regulate
global and selective protein synthesis during self-renewal and
differentiation [41]. Therefore, mTORC1 kinase activity may
serve a similar role in the regulation of osteosarcoma stem
cell proliferation and self-renewal.
Indeed, the ability of mTOR to promote proliferation
without differentiation has been demonstrated in the liter-
ature. Many studies have shown that rapamycin treatment
induces a G1-arrest in various cell lines, including osteosar-
coma [10, 34], and here we have shown that rapamycin has
a similar effect on K7M2 OS cells. This G1-arrest is likely
to occur through the down-regulation of cyclin D1 as was
previously shown in human OS cells by Gazitt et al. [42].
mTOR activity has also been shown to block differentiation as
rapamycin treatment can enhance osteoblast differentiation
[43]. Although an OS cancer stem cell has not been identified
to date, evidence is accumulating that suggests this discovery
ismerely amatter of time [44]. If anOS cancer stem cell exists,
we suspect that mTOR and ALDH activity play pivotal roles
in the maintenance of this subpopulation of cancer cells.
Here we also demonstrated that BMP2 andVEGF expres-
sion in K7M2 cells is reduced by rapamycin treatment.
Previously we had shown that BMP2 and VEGF expression
is upregulated in K7M2 cells compared to K12 cells [31].
Furthermore, treatment with the BMP antagonist Noggin
caused decreasedmotility, alteredmorphology, and increased
cell death in K7M2 cells. It is also known that BMP2 is
activated through hypoxia/AKT/mTOR/HIF𝛼 pathway in
osteoblasts [45]. VEGF, on the other hand, is a potent inducer
of neovascularization whose activity is thought to be an
absolute requirement for tumor growth and metastasis [46].
Consistent with the present study, rapamycin has been shown
to reduce VEGF production and inhibit angiogenesis in mice
in vivo [47]. Therefore, down-regulation of BMP2 and VEGF
(by mTORC1 inhibition) may each contribute to alter the
metastatic behavior of K7M2 cells. Both BMP2 and VEGF
may prove to be therapeutic targets in the treatment of OS
metastasis. In vivo studies are essential to investigate the role
of these secreted proteins in OS metastatic biology.
Our results show that ALDH inhibition via disulfiram
actually decreased mTOR activity. This implies that under
certain circumstances, mTOR activity may be regulated by
ALDH. This has profound implications as mTOR activity is
important in many cancers and is downstream of impor-
tant tumor suppressors and oncogenes that are frequently
mutated in human cancers [17]. Our work supports an
oncogenic role for mTORC1 activity in osteosarcoma and
provides evidence to link mTOR signaling, ALDH activity,
and metastatic behavior. To our knowledge the present study
is the first to implicate mTOR in the regulation of ALDH
activity. Given our data and other evidence that exists to
implicate mTOR and ALDH function in CSCs, we suspect
that if an OS stem cell exists, mTOR and ALDH may be
important for its proliferation, self-renewal, drug resistance,
cell survival, and metastasis. The search for surface markers
of OS cells has been long and disappointing, but ALDH may
represent great promise as an OS stem cell surface marker. At
this point in time we cannot be certain of the mechanisms
by which ALDH and mTOR interact. Future investigations
are required to further delineate the roles and relationships
of mTOR, ALDH, and OS cancer stem cells.
In conclusion, mTOR signaling is upregulated in highly
metastatic K7M2 OS cells. This upregulation is associated
with increased ALDH expression and activity, resistance to
oxidative stress, greater proliferation, migration, and inva-
sion, and higher BMP2 and VEGF expression. This work
implicates rapamycin and its analogs as potential agents in the
treatment and prevention of OS metastasis. It also suggests a
relationship between mTOR and ALDH. ALDH may, in its
own right, represent a possible marker and therapeutic target
of OS cell metastatic potential.
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